文献速递炎症性肠病

乌司奴单抗在炎症性肠病孕妇中的药物水平及宫内暴露婴儿的清除情况

Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
PubMed 文献 · Aliment Pharmacol Ther · 2021-12-14

这项前瞻性观察研究纳入19例接受乌司奴单抗治疗的炎症性肠病孕妇,发现孕期乌司奴单抗谷浓度稳定(P=0.83,n=11),婴儿分娩时药物水平高于母体(中位婴儿:母体比值1.79,IQR 1.26-3.1),母婴分娩水平正相关(r=0.75,P=0.001),婴儿中位清除时间为9周(范围6-19周,n=9)。作者结论认为乌司奴单抗在孕期药物水平似乎稳定,婴儿清除在产后20周内完成,但在获得进一步清除数据前,宫内暴露婴儿应避免在12月龄前接种活疫苗。

要点

  • 孕期乌司奴单抗谷浓度稳定(P=0.83,n=11)。
  • 婴儿分娩时乌司奴单抗水平高于母体,中位婴儿:母体比值1.79(IQR 1.26-3.1)。
  • 婴儿中位清除时间9周(范围6-19周,n=9);宫内暴露婴儿应避免12月龄前接种活疫苗。

核心结论

  • 乌司奴单抗在孕期药物水平似乎稳定,婴儿分娩时婴儿:母体比值与抗TNF类药物相似。
  • 婴儿乌司奴单抗清除在产后20周内完成;在获得进一步清除数据前,宫内暴露婴儿应避免在12月龄前接种活疫苗。

研究设计与样本

  • 前瞻性观察研究,纳入19例接受乌司奴单抗治疗的炎症性肠病孕妇。
  • 在孕期每个三月期及分娩时测量乌司奴单抗谷浓度,并在分娩时及清除前测量婴儿乌司奴单抗水平。
  • 采用Skillings-Mack检验比较个体孕期乌司奴单抗谷浓度稳定性,采用Spearman系数分析母婴分娩水平相关性,并定义婴儿乌司奴单抗清除的中位时间。

主要发现

  • 在有两次或以上代表性谷浓度的11例孕妇中,孕期乌司奴单抗水平无差异(P=0.83,n=11)。
  • 婴儿分娩时乌司奴单抗水平高于母体水平,中位婴儿:母体比值为1.79(IQR 1.26-3.1)。
  • 母婴分娩时乌司奴单抗水平呈正相关(r=0.75,P=0.001)。
  • 末次产前给药至分娩的天数与婴儿分娩时乌司奴单抗水平呈负相关(r=-0.65,P=0.006)。
  • 婴儿乌司奴单抗清除的中位时间为9周(范围6-19周,n=9)。

临床怎么用

  • 作者结论认为乌司奴单抗在孕期药物水平似乎稳定。
  • 作者建议在获得进一步清除数据前,宫内暴露婴儿应避免在12月龄前接种活疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ustekinumab is increasingly used in pregnant women with inflammatory bowel disease (IBD). Existing safety data are reassuring, but the stability of ustekinumab levels in pregnancy, degree of transfer to the infant and time to infant clearance are unknown. METHODS: In this prospective observational study, ustekinumab-exposed women with IBD had trough levels measured in each trimester of pregnancy and at delivery. Infant ustekinumab levels were measured at delivery and ongoing until clearance was achieved. Trough ustekinumab level stability in individuals across pregnancy was compared by Skillings-Mack test. Spearman coefficients were used to correlate maternal and infant delivery levels, and median time to infant ustekinumab clearance was defined. RESULTS: 19 pregnant women receiving ustekinumab were included. There was no difference in ustekinumab levels across pregnancy in those with two or more representative trough levels (P = 0.83, n = 11). Infant delivery ustekinumab levels were higher than maternal levels, with a median infant:maternal ratio of 1.79 (IQR 1.26-3.1). There was a positive correlation between maternal and infant delivery ustekinumab levels (r = 0.75, P = 0.001) and an inverse correlation between the number of days from final antenatal dose and delivery infant ustekinumab level (r = -0.65, P = 0.006). Median time of infant ustekinumab clearance was 9 (range 6-19) weeks (n = 9). CONCLUSION: Ustekinumab drug levels appear stable in pregnancy, with a delivery infant:maternal ratio similar to that of anti-TNFs. Infant ustekinumab clearance was complete by 20 weeks post-partum, however, infants exposed in utero should avoid live vaccination before 12 months of age until further clearance data are obtained.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Flanagan E, Prentice R, Wright EK, et al. Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Aliment Pharmacol Ther. 2021. PMID: 34907546. doi:10.1111/apt.16739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。